Metastatic progression in infants diagnosed with stage 4S neuroblastoma. A study of the Italian Neuroblastoma Registry.
metastatic progression
neuroblastoma
stage 4
stage 4S
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
revised:
14
12
2020
received:
16
11
2020
accepted:
31
12
2020
pubmed:
19
1
2021
medline:
15
10
2021
entrez:
18
1
2021
Statut:
ppublish
Résumé
Stage 4S neuroblastoma, a tumor affecting infants, is characterized by the capacity to regress spontaneously and high cure rate. About a third of these infants undergo tumor progression requiring antitumor treatment and 10-15% eventually die. In case of metastatic progression, it may occur either at 4S sites (mainly liver) or sites characterizing stage 4 (mainly bone). Aim of this study was to estimate incidence, presenting features and outcome of infants who progressed to stage 4S or stage 4 sites. Of 280 Italian infants diagnosed with stage 4S neuroblastoma between 1979 and 2013 and registered in the Italian Neuroblastoma Registry, 268 were evaluable for this study, of whom 57 developed metastatic progression. Progression to stage 4S sites occurred in 29/268 infants (10.8%) (Group A) and to stage 4 in 28/268 (10.4%) (Group B). No significant difference was observed between the two groups at the time of diagnosis. At the time of progression, Group A infants were younger (7.3 vs 14.4 months, P = .001) and had a shorter interval from diagnosis to progression (3.8 vs 9.6 months, P = .001). Survival after progression was worse for Group B infants (45% vs 69%, P = .058) and was associated with age at diagnosis lower than 2 months (P = .005) and adrenal primary tumor site (P = .008). Survival rates increased for both groups along the study period. Infants who progressed to stage 4 did worse, possibly in relation to older age at progression and longer interval between diagnosis and progression. Large prospective studies of these patients may lead to more effective treatments.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e28904Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Luksch R, Castellani MR, Collini P, et al. Neuroblastoma (peripheral neuroblastic tumours). Crit Rev Oncol Hematol. 2016;107:163-181.
D'Angio GJ, Evans AE, Koop C. Special pattern of widespread neuroblastoma with a favorable prognosis. Lancet. 1971;1:1046-1049.
Evans AE, Chatten J, D'Angio GJ, et al. A review of 17 IV-S neuroblastoma patients at the Children's Hospital of Philadelphia. Cancer. 1980;45:833-839.
Brodeur GM, et al. Spontaneous regression of neuroblastoma. Cell Tissue Res. 2018;372:277-286.
Blatt J, Deutsch M, Wollman MR. Results of therapy in stage IV-S neuroblastoma with massive hepatomegaly. Int J Radiat Oncol Biol Phis. 1987;13:1467-1471.
De Bernardi B, Pianca C, Boni L, et al. Disseminated neuroblastoma (stage IV and IV-S) in the first year of life. Outcome related to age and stage. Italian Cooperative Group on Neuroblastoma. Cancer. 1992;70:1625-1633.
Nickerson HJ, Matthay KK, Seeger RC, et al. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study. J Clin Oncol. 2000;18:477-486.
Schleiermacher G, Rubie H, Hartmann O, et al. Treatment of stage 4S neuroblastoma-report of 10 years’ experience of the French Society of Paediatric Oncology (SFOP). Br J Cancer. 2003;89:470-476.
De Bernardi B, Di Cataldo A, Garaventa A, et al. Stage 4S neuroblastoma: features, management and outcome of 268 cases from the Italian Neuroblastoma Registry. Ital J Pediatr. 2019;45:8.
Raitio A, Rice MJ, Mullassery D, Losty PD. Stage 4S neuroblastoma: what are the outcomes? A systematic review of published studies. Eur J Pediatr Surg. 2020. https://doi.org/10.1055/s-0040-1716836
Guglielmi M, De Bernardi B, Rizzo A, et al. Resection of primary tumor at diagnosis in stage IV-S neuroblastoma: does it affect the clinical course? J Clin Oncol. 1996;14:1537-1544.
Avanzini S, Buffoni I, Gigliotti AR, et al. Resection of primary tumor in stage 4S neuroblastoma: a second study of the Italian Neuroblastoma Group. Pediatr Surg Int. 2020. https://doi.org/10.1007/s00383-020-04766-1
Cohn SL, Pearson ADJ, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2009;27:289-297.
Schleiermacher G, Mosseri V, London WB, et al. Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project. Br J Cancer. 2012;107:1418-1422.
van Noesel MM, Hählen K, Hakvoort-Cammel FG. 4S: a heterogeneous disease with variable risk factors and treatment strategies. Cancer. 1997;80:834-843.
Tas ML, Nagtegaal M, Kraal KCJM, et al. Neuroblastoma stage 4S: tumor regression rate and risk factors of progressive disease. Pediatr Blood Cancer. 2020;67:e28061.
Schleiermacher G, Michon J, Ribeiro A, et al. Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study). Br J Cancer. 2011;105:1940-1948.
Haupt R, Garaventa A, Gambini C, et al. Improved survival of children with neuroblastoma between 1979 and 2005: a report of the Italian Neuroblastoma Registry. J Clin Oncol. 2010;28:2331-2338.
Shimada H, Ambros IM, Dehner LP, et al. The international neuroblastoma pathology classification (the Shimada system). Cancer. 1999;86:364-372.
Ambros PF, Ambros IM, Brodeur GM, et al. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer. 2009;100:1471-1482.
De Bernardi B, Gerrard M, Boni L, et al. Excellent out come with reduced treatment for infants with disseminated neuroblastoma woithout MYCN amplification. J Clin Oncol. 2009;27:1034-1040.
Cañete A, Gerrard M, Rubie H, et al. Poor survival for infants with MYCN-amplified metastic neurobolastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma experience. J Clin Oncol. 2009;27:1014-1019.
Viprey V, Corrias MV, Kagedal B, et al. Standardisation of operating procedures for the detection of minimal disease by QRT-PCR in children with neuroblastoma: quality assurance on behalf of SIOPEN-R-NET. Eur J Cancer. 2007;43:341-350.
Viprey VF, Gregory WM, Corrias MV, et al. Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: a European HR-NBL1/SIOPEN study. J Clin Oncol. 2014;32:1074-1083.
Hosmer DW, Lemeshow S. Applied Survival Analysis - Regression Modelling of Time to Event Data. New York: John Wiley & Sons, Inc; 1999.
Furlan A, Dyachuk V, Kastriti ME, et al. Multipotent peripheral glial cells generate neuroendocrine cells of the adrenal medulla. Science. 2017;357(6346):eaal3753.
Tsubota S, Kadomatsu K. Origin and initiation mechanisms of neuroblastoma. Cell Tissue Res. 2018;372:211-221.